QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
Top-Rated StocksTop-Rated
NASDAQ:RLAY

Relay Therapeutics (RLAY) Stock Forecast, Price & News

$8.32
-0.09 (-1.07%)
(As of 09/26/2023 ET)
Compare
Today's Range
$8.28
▼
$8.80
50-Day Range
$8.32
▼
$12.60
52-Week Range
$8.28
▼
$24.40
Volume
1.08 million shs
Average Volume
1.32 million shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.06
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Relay Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
213.2% Upside
$26.06 Price Target
Short Interest
Bearish
23.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Relay Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$47,336 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.29) to ($3.48) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

810th out of 964 stocks

Biological Products, Except Diagnostic Industry

128th out of 158 stocks

See Top Rated MarketRank™ Stocks Here

RLAY stock logo

About Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

RLAY Price History

RLAY Stock News Headlines

September 24, 2023 | americanbankingnews.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages
September 18, 2023 | finance.yahoo.com
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 26, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 9, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ansell (OtherANSLF) and Relay Therapeutics (RLAY)
August 9, 2023 | msn.com
Oppenheimer Reiterates Relay Therapeutics (RLAY) Outperform Recommendation
August 8, 2023 | finance.yahoo.com
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
August 8, 2023 | finance.yahoo.com
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 1, 2023 | finance.yahoo.com
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
September 26, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
July 28, 2023 | seekingalpha.com
Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608
July 3, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Relay Therapeutics (RLAY), Bright Health Group (BHG) and Bausch + Lomb Corporation (BLCO)
June 10, 2023 | msn.com
HC Wainwright & Co. Maintains Relay Therapeutics (RLAY) Buy Recommendation
June 9, 2023 | msn.com
11 Analysts Have This to Say About Relay Therapeutics
June 5, 2023 | markets.businessinsider.com
Barclays Sticks to Its Hold Rating for Relay Therapeutics (RLAY)
May 18, 2023 | finance.yahoo.com
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Deliver On Growth Plans?
May 12, 2023 | seekingalpha.com
Relay Therapeutics May 2023 Corporate Presentation
May 9, 2023 | seekingalpha.com
Relay Therapeutics: Selloff On Poor Breast Cancer Data May Have Been Overblown
May 9, 2023 | markets.businessinsider.com
Berenberg Bank Sticks to Their Buy Rating for Relay Therapeutics (RLAY)
May 5, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Relay Therapeutics (RLAY)
May 4, 2023 | msn.com
Relay Therapeutics: Q1 Earnings Insights
May 4, 2023 | finance.yahoo.com
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates
May 3, 2023 | msn.com
Earnings Outlook For Relay Therapeutics
April 26, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY) and CureVac (CVAC)
April 20, 2023 | msn.com
Stifel Maintains Relay Therapeutics (RLAY) Buy Recommendation
April 20, 2023 | msn.com
Jefferies Upgrades Relay Therapeutics (RLAY)
April 20, 2023 | markets.businessinsider.com
What 11 Analyst Ratings Have To Say About Relay Therapeutics
April 20, 2023 | finance.yahoo.com
4 big analyst picks: BofA ups composite decking stocks Azek, Trex | Pro Recap
See More Headlines
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLAY Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RLAY
CUSIP
N/A
CIK
1812364
Web
www.relaytx.com
Phone
617-370-8837
Fax
N/A
Employees
345
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.06
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$12.50
Forecasted Upside/Downside
+210.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-290,510,000.00
Net Margins
-36,562.53%
Pretax Margin
-36,562.53%
Return on Equity
-37.81%
Return on Assets
-32.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.35
Quick Ratio
12.36

Sales & Book Value

Annual Sales
$1.38 million
Price / Sales
742.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.86 per share
Price / Book
1.07

Miscellaneous

Outstanding Shares
122,130,000
Free Float
117,810,000
Market Cap
$1.02 billion
Optionable
Not Optionable
Beta
1.38
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Alexis A. Borisy A.M. (Age 51)
    Co-Founder & Independent Chairman
    Comp: $85k
  • Dr. Sanjiv K. Patel M.A. (Age 49)
    M.B.A., M.D., MBBS, CEO, Pres & Director
    Comp: $1.03M
  • Dr. Mark Murcko Ph.D. (Age 63)
    Co-Founder & Director
    Comp: $50k
  • Mr. Thomas CatinazzoMr. Thomas Catinazzo (Age 46)
    Chief Financial Officer
    Comp: $599.83k
  • Mr. Brian R. Adams J.D. (Age 49)
    Chief Legal Officer & Sec.
    Comp: $598.53k
  • Dr. Donald A. Bergstrom M.D.Dr. Donald A. Bergstrom M.D. (Age 51)
    Ph.D., Pres of R&D
    Comp: $711.25k
  • Mr. Peter Rahmer
    Chief Corp. Devel. Officer
  • Dr. Deborah Palestrant Ph.D.
    VP of Corp. Devel. & Strategy
  • Mr. Jim Watters Ph.D.
    Chief Scientific Officer of Late Research
  • Dr. Beni B. Wolf M.D.
    Ph.D., Chief Medical Officer & Head of Precision Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RLAY Stock - Frequently Asked Questions

Should I buy or sell Relay Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RLAY shares.
View RLAY analyst ratings or view top-rated stocks.

What is Relay Therapeutics' stock price forecast for 2023?

10 equities research analysts have issued 12 month target prices for Relay Therapeutics' stock. Their RLAY share price forecasts range from $12.50 to $34.00. On average, they predict the company's stock price to reach $26.06 in the next year. This suggests a possible upside of 210.6% from the stock's current price.
View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts.

How have RLAY shares performed in 2023?

Relay Therapeutics' stock was trading at $14.94 at the beginning of 2023. Since then, RLAY stock has decreased by 43.8% and is now trading at $8.39.
View the best growth stocks for 2023 here.

When is Relay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RLAY earnings forecast.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.03. The company earned $0.12 million during the quarter, compared to the consensus estimate of $0.81 million. Relay Therapeutics had a negative trailing twelve-month return on equity of 37.81% and a negative net margin of 36,562.53%. The company's quarterly revenue was down 67.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.71) earnings per share.

What ETFs hold Relay Therapeutics' stock?

ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), Range Cancer Therapeutics ETF (CNCR) and SPDR S&P Biotech ETF (XBI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

When did Relay Therapeutics IPO?

(RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

What is Relay Therapeutics' stock symbol?

Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."

Who are Relay Therapeutics' major shareholders?

Relay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.85%), State Street Corp (5.90%), Casdin Capital LLC (4.91%), JPMorgan Chase & Co. (4.09%), Bellevue Group AG (3.41%) and ArrowMark Colorado Holdings LLC (2.80%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Rock Ventures Iii LP Third, Sanjiv Patel and Thomas Catinazzo.
View institutional ownership trends.

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Relay Therapeutics' stock price today?

One share of RLAY stock can currently be purchased for approximately $8.39.

How much money does Relay Therapeutics make?

Relay Therapeutics (NASDAQ:RLAY) has a market capitalization of $1.02 billion and generates $1.38 million in revenue each year. The company earns $-290,510,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis.

How many employees does Relay Therapeutics have?

The company employs 345 workers across the globe.

How can I contact Relay Therapeutics?

Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.relaytx.com. The company can be reached via phone at 617-370-8837 or via email at prahmer@relaytx.com.

This page (NASDAQ:RLAY) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -